BLOOMFIELD, Conn., July 9, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) released its 2023 environmental, social, and governance (ESG) report, detailing the organization's ongoing efforts to strengthen communities and drive improvement to a more sustainable and equitable health care system.
"The Cigna Group is a purpose-built, high-performance organization dedicated to creating positive change around the world," said Geneva Brown, vice president, ESG and diversity, equity and inclusion, The Cigna Group. "We are committed to advancing our efforts to realize the vision we have for a better future built on the vitality of every individual and every community."
The Cigna Group's multi-dimensional ESG framework is based on four key pillars: Healthy Society, Healthy Workforce, Healthy Environment, and Healthy Company. The report includes key performance indicators, reporting, and recognitions. Learn more about the company's ESG efforts here.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions and has more than 187 million customer relationships around the world. Learn more at thecignagroup.com.
Media Contact
Madeline Ziomek
(202) 615-1473
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$276.92 |
Daily Change: | 2.12 0.77 |
Daily Volume: | 2,837,489 |
Market Cap: | US$77.030B |
October 31, 2024 September 12, 2024 September 12, 2024 August 01, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB